Ritonavir Amprenavir

Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine E, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J (2003a) A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in nonnucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 8 279-287... [Pg.197]

FLECAINIDE ANTIVIRALS - PROTEASE INHIBITORS Amprenavir, ritonavir and possibly saquinavir and tipranavir with ritonavir t flecainide levels, with risk of ventricular arrhythmias Uncertain possibly inhibition of CYP3A4- and CYP2D6-mediated metabolism of flecainide Manufacturers recommend avoiding co-administration of flecainide with amprenavir, ritonavir and saquinavir... [Pg.20]

TIPRANAVIR + RITONAVIR AMPRENAVIR + RITONAVIR Possibly 1 efficacy Significant l bioavailability Avoid co-administration... [Pg.624]

Alternatives Amprenavir/ritonavir plus lamivudine (or emtricitabine) plus zidovudine (or stavudine)... [Pg.2261]

Amprenavir/Ritonavir Appropriate dose not established. Care (unpredictable effect) 600/100 mg twice daily ... [Pg.789]

Preliminary data suggest that the combination of amprenavir 600 mg twice daily with lopinavir/ritonavir 400/100 mg twice daily resulted in amprenavir trough plasma levels that were lower than with the combination of amprenavir/ritonavir at the same doses. Similarly the lopinavir levels were lower than those without amprenavir. Others have reported similar findings, and increasing the dose of ritonavir did not prevent a decrease in amprenavir levels with lopinavir. Similar findings were also reported for fosamprenavir with lopinavir/ritonavir, and further study showed that separation of doses reduced the effect of amprenavir on lopinavir/ritonavir levels, but increased the effect on amprenavir levels. " However, the manufacturer notes that combining lopinavir/ritonavir 400/100 mg with fosamprenavir/ritonavir 700/100 mg, both twice daily, increased the AUC and minimum level of lopinavir by 37% and 52%, respectively, whereas the AUC and minimum level of amprenavir were decreased by 63% and 65%, respectively. " In addition, the US manufacturer says that the rate of adverse effects was higher with this combination. ... [Pg.822]

The AUC, minimum, and maximum levels of amprenavir 1.2 g twice daily were increased by 131%, 484%, and 33%, respectively, by ritonavir 200 mg twice daily. This agrees with in vitro data. The manufacturer recommends that doses of both protease inhibitors be reduced when they are used together. Based on modelling of pharmacokinetic data, a dose of amprenavir 600 mg with ritonavir 100 mg, both twice daily, has been suggested. This combination has shown good clinical efficacy in at least one study, and resulted in satisfactory amprenavir levels when efavirenz was also used" (see also NNRTIs + ftotease inhibitors , p.785). Amprenavir levels with fosamprenavir/ritonavir 700/100 mg twice daily were similar to those achieved with amprenavir/ritonavir 600/100 mg twice daily. ... [Pg.822]

If ritonavir is given as a pharmacokinetic booster the recommended dose is amprenavir/ritonavir 600/100 mg twice daily. [Pg.822]

In a clinical study of dual-boosted protease inhibitor combination therapy in multiple-treatment experienced HIV-positive adults there was a 55% reduction in minimum amprenavir levels when tipranavir/ritonavir 500/200 mg twice daily was added to amprenavir/ritonavir 600/100 mg twiee daily. " Therefore the use of tipranavir/ritonavir with amprenavir/ritonavir is not reeommended, as the clinical relevance of the reduction in amprenavir levels has not been established. If the combination is nevertheless considered necessary, a monitoring of the plasma levels of the protease inhibitors is strongly encouraged. "... [Pg.822]

There are reports of at least 9 other patients, including 2 children, who have developed Cushing s syndrome within 2 to 5 months of using regimens of inhaled " or intranasal fluticasone, with ritonavir, ritonavir/ amprenavir, ritonavir/lopinavir, ritonavir/saquinavir, ... [Pg.1060]

An HPLC method previously described for the assay of amprenavir, ritonavir, [20]... [Pg.116]

CodgUo, M. HiUaire-Buys, D. Peyriere, H. Ahic, R. Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma, J.Chromatogr.ScL, 2003, 41, 80-86. [efavirenz indinavir amprenavir ritonavir saquinavir nelflnavir]... [Pg.39]

Justesen, U.S. Pedersen, C. KUtgaard, NA. Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelflnavir and the nelflnavir active metabolite M8 in plasma by liquid chromatography, J.Chromatogr.B, 2003, 783, 491-500. [Pg.39]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...